Eisai
4523.T
$42.58
Share price
1.74%
Change (1 day)
-30.66%
Change (1 year)
Categories
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.
Revenue for Eisai (4523.T)
Revenue in 2024 (TTM): A$7.67 Billion
According to Eisai's latest financial reports the company's current revenue (TTM 
) is A$8.45 Billion. In 2023 the company made a revenue of A$7.76 Billion a decrease over the revenue in the year 2022 that were of A$8.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eisai from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | A$7.67 B | -1.17% |
| 2023 | A$7.76 B | -4.87% |
| 2022 | A$8.16 B | -6.99% |
| 2021 | A$8.77 B | 1.16% |
| 2020 | A$8.67 B | 0.15% |
| 2019 | A$8.66 B | 7.18% |
| 2018 | A$8.08 B | 24.33% |
| 2017 | A$6.49 B | -4.77% |
| 2016 | A$6.82 B | 5.99% |
| 2015 | A$6.44 B | 1.31% |
| 2014 | A$6.35 B | -4.47% |
| 2013 | A$6.65 B | -1.89% |
| 2012 | A$6.78 B | -16.47% |
| 2011 | A$8.11 B | -12.18% |
| 2010 | A$9.24 B | -0.58% |
| 2009 | A$9.29 B |